Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease
- 29 March 2023
- journal article
- review article
- Published by Wiley in Annals of Neurology
- Vol. 93 (5), 877-880
- https://doi.org/10.1002/ana.26643
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s DiseaseThe Journal Of Prevention of Alzheimer's Disease, 2022
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseNature Medicine, 2021
- Donanemab in Early Alzheimer’s DiseaseThe New England Journal of Medicine, 2021
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyAlzheimer's Research & Therapy, 2021
- Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approvalAlzheimer's Research & Therapy, 2020
- Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluidAnnals of Neurology, 2019
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s DiseaseThe New England Journal of Medicine, 2018
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s diseaseNature, 2016
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's DiseaseThe New England Journal of Medicine, 2014
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's DiseaseThe New England Journal of Medicine, 2013